Trial Profile
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled 26-Week Trial To Evaluate The Efficacy And Safety Of Dimebon In Patients With Moderate-To-Severe Alzheimer's Disease.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 23 Mar 2017
Price :
$35
*
At a glance
- Drugs Latrepirdine (Primary) ; Memantine
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacogenomic; Registrational; Therapeutic Use
- Acronyms CONSTELLATION
- Sponsors Pfizer
- 01 Oct 2012 Primary endpoint amended as reported by ClinicalTrials.gov. (Parent trial: NCT00912288)
- 01 Oct 2012 Primary endpoint amended as reported by ClinicalTrials.gov. (Parent trial: NCT00912288)
- 17 Jul 2012 Actual patient number changed from 89 to 86 as reported by ClinicalTrials.gov. (Parent trial: NCT00912288)